Genzyme will buy its cancer drug partner
639985
As part of its push to become a bigger player in cancer drugs, Genzyme Corp. of Cambridge said yesterday it will buy out business partner Bioenvision Inc. of New York for $345 million , consolidating its ownership of a cancer treatment to which the two companies had been sharing rights.
382580
Genzyme Corp. of Cambridge, Mass., agreed Thursday to buy back the sales and marketing rights for Synvisc, a pain treatment for people suffering from osteoarthritis of the knee, from Wyeth Pharmaceuticals of Collegeville, Pa.
471781
The company is ready to handle competition from generics.
421575
Genentech and OSI Pharmaceuticals won federal approval yesterday to sell Tarceva, a pill to treat lung cancer. The approval by the Food and Drug Administration came well before the agency&#39;s
26608
German and Swiss drug makers Schering and Novartis are developing a new anti-cancer drug with annual sales potential of up to two billion euros (2.7 billion dollars), Schering chief Hubertus Erlen said.
665690
The developing biopharmaceutical company announces a share offering.
681279
Genentech Inc said on Tuesday its cancer drug, Avastin, met the primary goal of prolonging progression-free survival when combined with chemotherapy in a breast cancer study, sending its shares up more than 3 percent.
421111
Genzyme Corp.  said on Friday its osteoarthritis pain treatment Synvisc will retain a separate, higher reimbursement rate, after the U.S. government reversed its earlier decision to cut the rate, sending Genzyme shares higher.
770040
An experimental antibody drug being developed by Danish biotech company Genmab and Britain's GlaxoSmithKline Plc confirmed its promise as a rheumatoid arthritis treatment on Friday.
227772
The pharmaceutical sells European rights to a promising asthma drug.
477715
Pharmaceutical group GlaxoSmithKline (GSK) has agreed to buy antibody therapy developer Domantis for 230 million pounds.
238851
Genzyme Corp.  said on Friday  its osteoarthritis pain treatment Synvisc will retain a  separate, higher reimbursement rate, after the U.S. government  reversed its earlier decision to cut the rate, sending Genzyme  shares higher.
517827
The drugmaker signed a deal to authorize a generic form of its osteoporosis drug Fosamax, which has annual sales of $3 billion, making it the worldâs top-selling drug for osteoporosis.
356950
Consolidation in Europe's drugs   sector gathered steam on Thursday as Germany's Merck unveiled a   $13.3-billion deal to buy Europe's top biotech firm Serono, and   Denmark's Nycomed won the drugs unit of Altana.
518270
AMSTERDAM -- Schering-Plough Corp. agreed to buy Akzo Nobel NV's drug-making division Organon for $14.4 billion to gain the world's third-largest maker of birth-control pills and a stable of experimental medicines.
124043
British pharmaceutical group GlaxoSmithKline (GSK) has said that it had agreed to buy antibody therapy developer Domantis for 230 million pounds (339 million euros, 451 million dollars) in cash.
18221
Genzyme has agreed to pay at least $325 million to win the hotly contested rights to a potentially powerful cholesterol-lowering drug.